Implementation of drug pricing provisions related to H.R. 5376 (P.L. 117-169), The Inflation Reduction Act. Issues related to safe mobility. Issues related to payment for prescription drugs. Issues concerning drug shortages. Issues related to extension of the hospital at home program and H.R. 7148 (P.L. 119-75), Consolidated Appropriations Act of 2026. Issues related to the Medicare Advantage star rating eye exam quality measure.
Lobbyists: MARY BETH SAVARY TAYLOR; GREG D'ANGELO; BRETT BAKER
Government entities lobbied:Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE
TAX — Taxation/Internal Revenue Code
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Monitor issues related to OECD Pillar 2.
Lobbyists: RACHEL JONES HENSLER; MOLLY FROMM
HCR — Health Issues
Monitored issues related to pharmaceutical prices. Issues regarding the pharmaceutical and medical device supply chain. Monitored issues concerning drug shortages. Issues concerning the reauthorization of Pandemic and All-Hazards Preparedness and Response Act (PAHPA). Monitored AI issues. Monitored cybersecurity issues. Issues concerning emergency preparedness and critical medical supplies. Issues concerning regulatory reforms.
Lobbyists: MARY BETH SAVARY TAYLOR; BRETT BAKER
Government entities lobbied:HOUSE OF REPRESENTATIVES; SENATE; White House Office
TRD — Trade (domestic/foreign)
Issues related to tariffs.
Lobbyists: RACHEL JONES HENSLER; MARY BETH SAVARY TAYLOR; MOLLY FROMM
Government entities lobbied:Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; White House Office
pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.
Estimated value: $180/mo per user — but we made it free.